Zanubrutinib for the treatment of MYD88 wild-type Waldenstrom macroglobulinemia: a substudy of the phase 3 ASPEN trial

Meletios Dimopoulos; Ramon Garcia Sanz; Hui-Peng Lee; Marek Trneny; Marzia Varettoni; Stephen Opat; Shirley D'Sa; Roger G Owen; Gavin Cull; Stephen Mulligan; Jaroslaw Czyz; Jorge J Castillo; Marina Motta; Tanya Siddiqi; Mercedes Gironella Mesa; Miquel Granell Gorrochategui; Dipti Talaulikar; Pier Luigi Zinzani; Elham Askari; Sebastian Grosicki; Albert Oriol; Simon Rule; Janusz Kloczko; Alessandra Tedeschi; Christian Buske; Veronique Leblond; Judith Trotman; Wai Y Chan; Jan Michel; Jingjing Schneider; Ziwen Tan; Aileen Cohen; Jane Huang; Constantine S Tam

Journal article

Zanubrutinib for the treatment of MYD88 wild-type Waldenstrom macroglobulinemia: a substudy of the phase 3 ASPEN trial

Meletios Dimopoulos, Ramon Garcia Sanz, Hui-Peng Lee, Marek Trneny, Marzia Varettoni, Stephen Opat, Shirley D'Sa, Roger G Owen, Gavin Cull, Stephen Mulligan, Jaroslaw Czyz, Jorge J Castillo, Marina Motta, Tanya Siddiqi, Mercedes Gironella Mesa, Miquel Granell Gorrochategui, Dipti Talaulikar, Pier Luigi Zinzani, Elham Askari, Sebastian Grosicki Show all

Blood Advances | AMER SOC HEMATOLOGY | Published : 2020

DOI: 10.1182/bloodadvances.2020003010

University of Melbourne Researchers

Constantine Tam Author Medicine - St Vincent's Hospital

Grants

Funding Acknowledgements

This study was supported by research funding from BeiGene Inc., US; and medical writing and editorial assistance were funded by BeiGene and provided by Gordon Bray and Bio Connections, LLC.